Phospho-FANCD2 (Ser222) Antibody

What is the biological significance of FANCD2 Ser222 phosphorylation?

FANCD2 Ser222 phosphorylation represents a critical regulatory mechanism in the DNA damage response pathway. This modification is initiated by ATM (Ataxia Telangiectasia Mutated) kinase and serves as a crucial signaling event that contributes to arresting cells in the S phase of the cell cycle following DNA damage . The phosphorylation at Ser222 operates within the broader context of FANCD2's role as the focal point of Fanconi anemia (FA) signaling, which coordinates multiple aspects of cellular responses to genotoxic stress .

Unlike FANCD2 monoubiquitination, which is commonly defective in FA cells exposed to various genotoxic stresses, Ser222 phosphorylation represents a distinct regulatory mechanism specifically linking FANCD2 to ATM signaling pathways . This phosphorylation event contributes to checkpoint mechanisms that determine whether cells will arrest proliferation, resume division, or undergo apoptosis when faced with DNA damage .

How do I select appropriate experimental controls when using Phospho-FANCD2 (Ser222) antibodies?

Selecting rigorous controls is essential for accurate interpretation of Phospho-FANCD2 (Ser222) antibody results. For primary validation, incorporate the following controls:

• Phosphatase treatment control: Treat duplicate samples with lambda phosphatase before immunoblotting to confirm signal specificity for the phosphorylated form of FANCD2.

• ATM inhibition control: Since FANCD2 Ser222 phosphorylation is ATM-dependent, include samples treated with specific ATM inhibitors to demonstrate reduced signal .

• FANCD2-deficient cells: PD20 cells or FANCD2 knockout cell lines provide excellent negative controls . These can be complemented with FANCD2-restored cells to demonstrate antibody specificity.

• Irradiation-induced phosphorylation: Compare non-irradiated versus irradiated samples, as DNA damage induces FANCD2 Ser222 phosphorylation .

For western blotting applications, note that FANCD2 presents as two forms: FANCD2-S (155 kDa) and FANCD2-L (230 kDa) , and appropriate molecular weight markers should be used to distinguish these forms.

What dilution parameters are optimal for detecting Phospho-FANCD2 (Ser222) in different experimental systems?

Optimal dilution parameters vary significantly depending on the experimental system and cell type. Based on accumulated research experience, the following protocol-specific dilutions provide reliable results:

When working with novel cell types or tissues, I recommend performing initial titration experiments with dilutions ranging from 1:50 to 1:500 to determine optimal signal-to-noise ratios. Different antibody preparations may require adjustment of these parameters, particularly when using unpurified antisera versus affinity-purified antibodies .

How does ATM-dependent phosphorylation of FANCD2 at Ser222 functionally differ from ATR-mediated regulation of the FANCD2-FANCI complex?

The regulation of FANCD2 involves distinct kinase-dependent pathways that produce fundamentally different functional outcomes:

ATM-dependent Ser222 phosphorylation of FANCD2 primarily contributes to the S-phase cell cycle checkpoint following DNA damage . This mechanism enables FANCD2 to function in signal transduction within the ATM pathway. Interestingly, studies using knockout mouse models revealed that Fancd2-deficient cells maintained an intact ATM-dependent S-phase checkpoint despite the absence of Ser222 phosphorylation . This suggests that while important, this modification may have redundant mechanisms in mice but not necessarily in humans.

In contrast, ATR-mediated phosphorylation targets FANCI within the FANCD2-FANCI complex, which is essential for most functions of FANCD2 within the FA signaling pathway . The FANCD2-FANCI complex operates in non-ubiquitinated states when initially recruited to DNA interstrand crosslinks, with subsequent modifications regulating its repair activities .

These distinct regulatory mechanisms allow FANCD2 to participate in multiple aspects of the DNA damage response through different protein complexes and post-translational modification states, enabling integration of various DNA damage signals and appropriate cellular responses.

What methodological approaches effectively distinguish between phosphorylated and monoubiquitinated FANCD2 forms in experimental systems?

Distinguishing between phosphorylated and monoubiquitinated FANCD2 forms requires specialized experimental approaches:

1. Sequential Immunoprecipitation Strategy:

• First immunoprecipitation: Use phospho-specific antibodies against FANCD2 (Ser222)

• Second immunoprecipitation: Use anti-ubiquitin antibodies on the first precipitate

• Analysis: Western blot to determine overlap between phosphorylated and ubiquitinated populations

2. Molecular Weight Separation:
The two major forms of FANCD2 have distinct molecular weights:

• FANCD2-S (non-ubiquitinated): 155 kDa

• FANCD2-L (monoubiquitinated): 230 kDa
  Phosphorylation at Ser222 can occur on either form, potentially creating four distinct populations.

3. Phosphatase and Deubiquitinase Treatments:

• Parallel samples treated with lambda phosphatase, USP1 (deubiquitinase), or both

• Western blot analysis comparing migration patterns and reactivity with specific antibodies

4. Site-Specific Mutant Constructs:

• Complementation of FANCD2-deficient cells with:

  • Wild-type FANCD2

  • S222A mutant (prevents phosphorylation)

  • K561R mutant (prevents monoubiquitination)

  • Double mutant (S222A/K561R)

• Comparative analysis of DNA damage responses and repair functions

These approaches enable researchers to delineate the specific contributions of each post-translational modification to FANCD2 function in different cellular contexts and in response to various DNA-damaging agents.

How can researchers interpret Phospho-FANCD2 (Ser222) antibody results in the context of Fanconi anemia research models?

Interpreting Phospho-FANCD2 (Ser222) antibody results in Fanconi anemia research requires careful consideration of model-specific characteristics and experimental conditions:

In Mouse Models:
Studies with Fancd2 knockout mice demonstrated that while these animals exhibited cellular sensitivity to DNA interstrand cross-links and germ cell loss (similar to human FA patients), they showed different responses to irradiation compared to expectations based on cell culture studies . Specifically:

• The LD50 for Fancd2 mutant mice was approximately 9.5 Gy compared to 11 Gy for non-mutant littermates, representing a proportional difference of ~1.15

• This sensitivity was similar to that observed in Fancc mutants, suggesting partially overlapping functions

• Importantly, Fancd2-null primary cells did not display radiation-resistant DNA synthesis, unlike Atm mutants

• This indicates that in murine primary cells, Fancd2 is not essential for the ATM-mediated S-phase arrest following irradiation

In Human Cell Lines:
When using human cell models, researchers should consider:

• Different cell types show varying levels of endogenous Phospho-FANCD2 (Ser222), requiring adjustment of antibody dilutions (1:100 for HeLa cells versus 1:400 for FANCD2-overexpressing cells)

• The phosphorylation status of FANCD2 at Ser222 should be evaluated in context with other FANCD2 modifications, particularly monoubiquitination, which is commonly defective in FA cells exposed to genotoxic stresses

• The relationship between ATM-dependent phosphorylation and ATR-dependent regulation of the FANCD2-FANCI complex provides important mechanistic insights into pathway integration

These considerations help researchers accurately interpret antibody results and place their findings within the broader context of Fanconi anemia pathway regulation and function.

What are the most effective protocols for detecting endogenous Phospho-FANCD2 (Ser222) in different experimental systems?

Detecting endogenous Phospho-FANCD2 (Ser222) requires optimized protocols tailored to specific experimental systems:

For Western Blot Detection:

• Sample Preparation:

  • Harvest cells in ice-cold PBS containing phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4)

  • Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitor cocktail, and phosphatase inhibitors

  • Sonicate briefly to shear DNA and clarify lysates by centrifugation (14,000×g, 10 min, 4°C)

• Gel Electrophoresis:

  • Use 6% SDS-PAGE gels to effectively resolve the high molecular weight FANCD2 forms (155 kDa FANCD2-S and 230 kDa FANCD2-L)

  • Load 50-100 μg total protein per lane

  • Include molecular weight markers spanning 100-250 kDa range

• Transfer and Detection:

  • Transfer proteins to PVDF membrane using wet transfer (25V overnight at 4°C)

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

  • Incubate with Phospho-FANCD2 (Ser222) antibody at dilutions optimized for cell type (1:100-1:400)

  • Use HRP-conjugated secondary antibodies and enhanced chemiluminescence detection

For Immunofluorescence:

• Cell Preparation:

  • Grow cells on coverslips, treat as desired, and fix with 4% paraformaldehyde

  • Permeabilize with 0.2% Triton X-100 in PBS

  • Block with 3% BSA, 0.1% Triton X-100 in PBS

• Antibody Incubation:

  • Incubate with Phospho-FANCD2 (Ser222) antibody (1:50-1:200 dilution)

  • Co-stain with antibodies against γH2AX or other DNA damage markers

  • Use appropriate fluorescent secondary antibodies

• Imaging:

  • Examine using confocal microscopy for optimal resolution of nuclear foci

  • Include DAPI staining to visualize nuclei

  • Quantify foci using image analysis software

These protocols can be modified based on specific experimental requirements and cell types, with particular attention to phosphatase inhibition throughout all procedures to preserve the phosphorylation signal.

How can researchers address common technical challenges when working with Phospho-FANCD2 (Ser222) antibodies?

Researchers frequently encounter several technical challenges when working with Phospho-FANCD2 (Ser222) antibodies. Here are evidence-based solutions to these common issues:

Challenge 1: Weak or Absent Signal

• Solution: Enhance phosphoprotein preservation by adding phosphatase inhibitors (10 mM NaF, 1 mM Na3VO4, 1 mM β-glycerophosphate) to all buffers

• Solution: Increase protein loading (75-100 μg per lane) for Western blots when detecting endogenous levels

• Solution: Use signal enhancement systems such as biotin-streptavidin amplification for immunohistochemistry

• Solution: Induce FANCD2 phosphorylation with appropriate DNA-damaging agents (10 Gy ionizing radiation or 40 J/m² UV) prior to analysis

Challenge 2: High Background or Non-specific Binding

• Solution: Use 5% BSA instead of milk for blocking (milk contains phosphatases)

• Solution: Increase antibody dilution (start with 1:500 and adjust as needed)

• Solution: Include additional washing steps (5× 5 minutes with TBST)

• Solution: Pre-clear lysates with protein A/G beads before immunoprecipitation

Challenge 3: Difficulty Distinguishing Specific Band

• Solution: Include positive control lysates from cells with known FANCD2 phosphorylation status

• Solution: Run parallel gels with total FANCD2 antibody for comparison

• Solution: Note that FANCD2 can appear as two forms: 155 kDa (FANCD2-S) and 230 kDa (FANCD2-L)

• Solution: Include ATM-inhibitor treated samples as negative controls

Challenge 4: Inconsistent Results Across Experiments

• Solution: Standardize cell treatment conditions (time post-damage is critical)

• Solution: Normalize phospho-signal to total FANCD2 levels

• Solution: Use fresh antibody aliquots; avoid repeated freeze-thaw cycles

• Solution: Validate antibody lot-to-lot consistency with known positive controls

These methodological approaches help address the technical variability inherent in phospho-specific antibody applications while maximizing sensitivity and specificity for accurate experimental outcomes.

What are the experimental design considerations for studying FANCD2 Ser222 phosphorylation in cancer research models?

Studying FANCD2 Ser222 phosphorylation in cancer research models requires careful experimental design that accounts for both biological complexity and technical considerations:

1. Model Selection Considerations:

FANCD2 is highly expressed in specific tissues that should inform model selection:

• Germinal center cells of the spleen, tonsil, and reactive lymph nodes

• Proliferating basal layer of squamous epithelium (tonsil, esophagus, oropharynx, larynx, cervix)

• Cytotrophoblastic cells of the placenta and exocrine cells of the pancreas

• Testis

Cancer models derived from these tissues may provide more relevant data on phosphorylation-dependent mechanisms.

2. Experimental Controls for Cancer Studies:

3. Therapeutic Response Assessment:

FANCD2 Ser222 phosphorylation status may predict response to:

• PARP inhibitors

• Platinum-based chemotherapeutics

• ATM/ATR inhibitors

• Radiation therapy

Experimental designs should include:

• Pre- and post-treatment phosphorylation analysis

• Correlation with clinical outcomes in patient-derived models

• Assessment of potential synthetic lethality approaches

4. Technical Implementation for Cancer Tissues:

When studying patient-derived materials:

• Preserve phosphorylation status through rapid fixation or flash freezing

• Use phospho-specific antibodies at optimized dilutions (typically 1:100-1:200 for IHC)

• Employ dual staining with proliferation markers (Ki-67) to correlate with cell cycle status

• Consider laser capture microdissection to isolate specific tumor regions

These experimental design considerations enhance the translational relevance of FANCD2 Ser222 phosphorylation studies in cancer research while addressing the technical challenges inherent in phosphoprotein analysis in complex tissue samples.

How does FANCD2 Ser222 phosphorylation coordinate with other DNA damage response pathways?

FANCD2 Ser222 phosphorylation functions as a critical integration point between multiple DNA damage response pathways, orchestrating a coordinated cellular response to genomic insults:

ATM-FANCD2-Checkpoint Coordination:
FANCD2 phosphorylation at Ser222, initiated by ATM, contributes to arresting cells in the S phase of the cell cycle . This phosphorylation event allows FANCD2 to perform signaling transduction roles within the ATM pathway, connecting DNA damage detection to cell cycle control mechanisms . This relationship highlights FANCD2's role beyond the classical Fanconi anemia pathway, positioning it as a multifunctional regulator in DNA damage responses.

FANCD2-BLM Pathway Integration:
BLM (Bloom syndrome protein) involvement in FANCD2 activation represents another critical pathway intersection . These proteins colocalize at nuclear foci during S phase and following genotoxic stress . They are frequently interlinked through ultra-fine DNA bridges and coincide with common fragile sites that may represent stalled replication forks . This interaction is particularly relevant for maintaining genome stability and proper replication fork progression.

FANCD2-H2AX-ATM Signaling Loop:
FANCD2 is required for proper phosphorylation of H2AX and subsequent ATM activation in certain cell types (e.g., rhabdomyosarcoma Rh30 cells) . This creates a potential feedback loop where:

• DNA damage activates ATM

• ATM phosphorylates FANCD2 at Ser222

• Phosphorylated FANCD2 contributes to H2AX phosphorylation

• Phosphorylated H2AX facilitates further ATM activation

This mechanism extends FANCD2's role beyond being a substrate in DNA damage signaling to actively participating in signal amplification and maintenance.

Enzymatic Regulation by FANCD2:
FANCD2 modulates the enzymatic activities of FAN1 (Fanconi-associated nuclease 1) and polymerase eta . These interactions directly influence the execution of DNA repair processes, suggesting that FANCD2 phosphorylation status may regulate repair pathway choice or efficiency through protein-protein interactions.

These coordinated interactions position FANCD2 Ser222 phosphorylation as a regulatory node that integrates damage detection, signaling transduction, cell cycle control, and repair pathway selection—providing cells with a mechanism to orchestrate appropriate responses to different types and magnitudes of DNA damage.

What are the latest methodological advances for studying the temporal dynamics of FANCD2 Ser222 phosphorylation?

Recent methodological advances have significantly enhanced researchers' ability to study the temporal dynamics of FANCD2 Ser222 phosphorylation:

1. Live-Cell Imaging Technologies:

• FRAP-based approaches: Fluorescence recovery after photobleaching using fluorescently-tagged FANCD2 with phospho-specific sensors

• FRET-based biosensors: Custom-designed sensors that undergo conformational changes upon FANCD2 Ser222 phosphorylation, allowing real-time monitoring of modification status

• Optogenetic systems: Light-inducible ATM activation combined with phospho-specific antibody detection for precise temporal control

2. Advanced Microscopy for Spatiotemporal Analysis:

• Super-resolution microscopy: Techniques like STORM and PALM provide nanoscale resolution of FANCD2 localization at damage sites

• 4D imaging: Time-lapse confocal microscopy with 3D reconstruction to track phosphorylated FANCD2 movement through nuclear compartments

• Correlative light-electron microscopy (CLEM): Combining fluorescence imaging of phospho-FANCD2 with ultrastructural analysis

3. Quantitative Phosphoproteomics:

• Stable isotope labeling approaches: SILAC or TMT labeling for quantitative comparison of phosphorylation dynamics

• Targeted mass spectrometry: Multiple reaction monitoring (MRM) for absolute quantification of Ser222 phosphorylation stoichiometry

• Phospho-enrichment strategies: Titanium dioxide or immobilized metal affinity chromatography combined with high-resolution mass spectrometry for comprehensive phosphorylation site analysis

4. Single-Cell Analysis Technologies:

• Mass cytometry (CyTOF): Antibody-based detection of phospho-FANCD2 in combination with other cellular markers at single-cell resolution

• Single-cell western blotting: Microfluidic platforms for analyzing FANCD2 phosphorylation in individual cells

• scRNA-seq with protein detection: Combined transcriptome and phospho-protein analysis to correlate FANCD2 phosphorylation with gene expression changes

These methodological advances enable researchers to monitor FANCD2 Ser222 phosphorylation with unprecedented temporal resolution, spatial precision, and quantitative accuracy—revealing the dynamic nature of this modification in response to different types of DNA damage and throughout various phases of the cell cycle.

How do FANCD2 knockout models inform our understanding of Ser222 phosphorylation in vivo?

FANCD2 knockout models have provided crucial insights into the biological significance of Ser222 phosphorylation in vivo, revealing both expected phenotypes and surprising discrepancies between in vitro and in vivo findings:

Phenotypic Characteristics of Fancd2 Knockout Mice:
Fancd2 mutant mice exhibited several characteristics consistent with human Fanconi anemia, including:

• Cellular sensitivity to DNA interstrand cross-links

• Germ cell loss

• Chromosome mispairing in male meiosis

These phenotypes confirm FANCD2's role in maintaining genomic integrity in vivo, providing a foundation for understanding phosphorylation-specific functions.

Unexpected Findings Regarding Radiation Sensitivity:
Studies with Fancd2 knockout mice revealed important discrepancies between in vitro predictions and in vivo observations:

• The LD50 for Fancd2 mutants was approximately 9.5 Gy compared with 11 Gy for nonmutant littermate controls (proportional difference ~1.15)

• This sensitivity was identical to that previously reported for Fancc mutants (proportional difference of ~1.2)

• Despite expectations based on cell culture studies linking Ser222 phosphorylation to ATM-mediated responses, Fancd2-deficient cells did not display radiation-resistant DNA synthesis (a hallmark of Atm mutants)

• Primary Fancd2-deficient cells maintained an intact ATM-dependent S-phase checkpoint following ionizing radiation

These findings suggest that in murine primary cells, Fancd2 is not essential for the ATM-mediated S-phase arrest following IR, indicating potential redundancy or compensatory mechanisms in vivo that are not apparent in vitro systems .

Insights for Translational Research:
The knockout model findings have important implications for understanding the role of FANCD2 Ser222 phosphorylation in human disease contexts:

• The differential requirement for FANCD2 in S-phase checkpoint maintenance between in vitro and in vivo systems suggests context-dependent functions that must be considered when targeting this pathway therapeutically.

• The similar radiation sensitivity phenotypes between Fancd2 and Fancc mutants suggests partially overlapping functions in vivo, which may inform combinatorial approaches when targeting FA pathway components.

• The phenotypic differences between Atm and Fancd2 mutants indicate that while FANCD2 is a substrate of ATM, its phosphorylation at Ser222 may represent just one of multiple redundant mechanisms through which ATM regulates the S-phase checkpoint in vivo.

What emerging roles for FANCD2 Ser222 phosphorylation might impact future research directions?

Recent discoveries suggest several emerging roles for FANCD2 Ser222 phosphorylation that will likely shape future research priorities in this field:

Replication Fork Protection:
FANCD2 has been identified at common fragile sites and regions of replication fork stalling . The phosphorylation at Ser222 may regulate FANCD2's ability to protect stalled replication forks from degradation, a function distinct from its role in interstrand crosslink repair. Future research will likely explore how this phosphorylation affects interactions with fork protection factors and influences genomic stability in highly replicative tissues.

Chromatin Dynamics and Nuclear Architecture:
The observation that FANCD2 concentrates in nuclear foci during S phase and upon genotoxic stress, but is excluded from chromosomes at the onset of mitosis , suggests phosphorylation-dependent regulation of its chromatin association. This dynamic localization may represent a previously unappreciated role in maintaining nuclear architecture, particularly at difficult-to-replicate regions of the genome.

Cancer Therapy Resistance Mechanisms:
The relationship between FANCD2 Ser222 phosphorylation and response to DNA-damaging therapies suggests potential applications in predicting treatment resistance. Future research will likely investigate whether phosphorylation status could serve as a biomarker for selecting patients who might benefit from ATM inhibitors or other targeted therapies in combination with conventional chemotherapeutics.

Intersection with Cellular Metabolism:
Emerging evidence suggests connections between DNA damage response pathways and cellular metabolic states. FANCD2 Ser222 phosphorylation may serve as an integration point between genomic stress and metabolic adaptation, potentially influencing cell fate decisions in contexts such as cancer and aging.

Developmental Regulation:
The high expression of FANCD2 in specific tissues such as germinal centers, squamous epithelium, cytotrophoblastic cells, and testis suggests tissue-specific functions that may be regulated by phosphorylation. Future research may uncover developmental roles for FANCD2 Ser222 phosphorylation in tissue homeostasis and regeneration.

These emerging directions highlight the expanding significance of FANCD2 Ser222 phosphorylation beyond its initially characterized role in DNA damage response, suggesting a multifaceted regulatory function that influences diverse cellular processes with implications for both basic science and translational medicine.

How might integrated multi-omics approaches advance our understanding of FANCD2 phosphorylation networks?

Integrated multi-omics approaches offer unprecedented opportunities to comprehensively map FANCD2 phosphorylation networks and their functional implications:

Phosphoproteomics-Transcriptomics Integration:
Combining phosphoproteomic profiling of FANCD2 Ser222 phosphorylation with RNA-seq analysis enables researchers to:

• Identify gene expression changes directly correlated with FANCD2 phosphorylation status

• Discover transcription factors and chromatin modifiers affected by FANCD2 phosphorylation

• Map temporal relationships between phosphorylation events and transcriptional responses

Interactome Dynamics Analysis:
Proximity labeling approaches (BioID, APEX) coupled with mass spectrometry can reveal:

• Dynamic changes in FANCD2 protein interactions based on phosphorylation status

• Condition-specific interaction networks (e.g., different DNA damage types)

• Secondary interactors affected by primary phosphorylation events

Chromatin Association Mapping:
Integration of ChIP-seq data with phosphoproteomics can reveal:

• Genomic regions where phosphorylated FANCD2 preferentially associates

• Temporal changes in chromatin binding following DNA damage

• Co-occupancy with other DNA repair factors dependent on phosphorylation status

Metabolomic Correlations:
Combining metabolomic profiling with phosphoproteomic data could uncover:

• Metabolic signatures associated with FANCD2 phosphorylation states

• Potential metabolic vulnerabilities in cells with aberrant FANCD2 phosphorylation

• Bidirectional regulatory relationships between metabolism and DNA damage responses

Clinical Data Integration:
Multi-omics integration with patient data can provide:

• Correlations between FANCD2 phosphorylation patterns and clinical outcomes

• Identification of biomarkers for treatment response prediction

• Novel therapeutic targets within the FANCD2 phosphorylation network

These integrated approaches would address the current limitations of studying phosphorylation events in isolation, providing a systems-level understanding of how FANCD2 Ser222 phosphorylation coordinates cellular responses across multiple molecular domains. Such comprehensive mapping would likely identify unexpected pathway connections and potential therapeutic vulnerabilities that remain obscured in more narrowly focused studies.